Duff Wilson, New York Times; Plan Would Delay Sales of Generic for Lipitor:
"Pfizer has agreed to large discounts for benefit managers that block the use of generic versions of Lipitor, according to a letter from Catalyst Rx, a benefit manager for 18 million people in the United States. The letters have not previously been made public.
A pharmacy group and an independent expert say the tactic will benefit Pfizer and benefit managers at the expense of employers and taxpayers, who may end up paying more than they should for the drug...
“I’m stunned,” said Geoffrey F. Joyce, an associate professor of pharmaceutical economics and a health policy expert at the University of Southern California, after reviewing the letters. “This is just an egregious case."
Issues and developments related to ethics, information, and technologies, examined in the ethics and intellectual property graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology" will be published in Summer 2025. Kip Currier, PhD, JD
Showing posts with label Pharmacists United for Truth and Transparency. Show all posts
Showing posts with label Pharmacists United for Truth and Transparency. Show all posts
Sunday, November 13, 2011
Plan Would Delay Sales of Generic for Lipitor; New York Times, 11/12/11
Subscribe to:
Posts (Atom)